Last reviewed · How we verify

BMS-986374 — Competitive Intelligence Brief

BMS-986374 (BMS-986374) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PRMT5 inhibitor. Area: Oncology.

marketed PRMT5 inhibitor PRMT5 (Protein Arginine Methyltransferase 5) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BMS-986374 (BMS-986374) — Bristol-Myers Squibb. BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BMS-986374 TARGET BMS-986374 Bristol-Myers Squibb marketed PRMT5 inhibitor PRMT5 (Protein Arginine Methyltransferase 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PRMT5 inhibitor class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMS-986374 — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-986374. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: